ARDS Clinical Trial
Official title:
Lung Imaging for Ventilatory Setting in ARDS
To compare in ARDS patients 2 ventilatory Strategies : One based on Lung Morphology (Focal
versus non-Focal ARDS) versus ARDS networks Guidelines (PEEP based on FiO2). In Focal ARDS
prone position will be promote early, with low PEEP and moderate Vt. In non-Focal ARDS,
Recruitment maneuvers, high PEEP and low V twill be used.
The investigators made the hypothesis that ventilation according to Lung morphology my
decrease mortality at D90.
Early ARDS, less than 12 hours will be included. After Lung imaging, they will be randomized to a control group (PEEP/FiO2 according to ARDSnetwork tables) or an intervention arm. In this arm, mechanical ventilation will be set according to lung morphology. In patients with focal ARDS, prone position will be start quickly for at least 16 hours. After, A low PEEP and 8ml/kg of PBWwill be used. In non-focal ARDS, a recruitment maneuver followed by a high PEEP and a small tidal volume strategy will be used. In both arms, patients will be sedated and paralyzed during maximum 48 hours. As soon as PaO2/FiO2 > 200 mmHG, myorelaxant and sedation will be withdrawal. Pressure support ventilation will be used as soon as possible and weaning from ventilation will be checked everyday ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04435613 -
Clinical and Physiological Assessment of a Nearly Ultra-protective Lung Ventilation Strategy: A Quasi-experimental Preliminary Study in ARDS Patients
|
N/A | |
| Enrolling by invitation |
NCT05020210 -
Effect of Early Treatment With Sivelestat Sodium in ARDS Patients
|
||
| Completed |
NCT04468971 -
REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia
|
Phase 1 | |
| Completed |
NCT04505592 -
Tenecteplase in Patients With COVID-19
|
Phase 2 | |
| Completed |
NCT04493242 -
Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS
|
Phase 2 | |
| Withdrawn |
NCT04909879 -
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome
|
Phase 2 | |
| Completed |
NCT02265198 -
Relationship of Pulmonary Contusion to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome
|
N/A | |
| Completed |
NCT01949272 -
Optimization of PEEP for Alveolar Recruitment in ARDS
|
N/A | |
| Not yet recruiting |
NCT01668368 -
Goal Directed Mechanical Ventilation Aimed at Optimal Lung Compliance
|
N/A | |
| Completed |
NCT01881061 -
Lung Sonography in Patients With Acute Respiratory Distress Syndrome in Intensive Care Unit
|
N/A | |
| Completed |
NCT00808691 -
Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit
|
N/A | |
| Completed |
NCT05035589 -
The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
|
||
| Recruiting |
NCT04764032 -
Right Ventricular Dysfunction in Ventilated Patients With COVID-19
|
||
| Completed |
NCT04556513 -
Functional Recovery From Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19: Influence of Socio-Economic Status
|
||
| Recruiting |
NCT06036056 -
NMR Based Metabolomics Kinetics in ARDS Patients
|
||
| Recruiting |
NCT04503876 -
Effects of End-expiratory Positive Pressure Optimization in Intubated Patients With Healthy Lung or Acute Respiratory Distress Syndrome
|
N/A | |
| Recruiting |
NCT04643691 -
Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS
|
Phase 2 | |
| Completed |
NCT04395911 -
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections
|
N/A | |
| Not yet recruiting |
NCT05341687 -
Prognostic Value of Respiratory System Compliance Under VV-ECMO on 180-day Mortality in COVID-19 ARDS.
|
||
| Recruiting |
NCT05056090 -
Effect of Prone Positioning on Mortality in Patients With Mild to Moderate Acute Respiratory Distress Syndrome.
|
N/A |